Ovid Therapeutics Future Growth
Future criteria checks 2/6
Ovid Therapeutics is forecast to grow earnings and revenue by 1.1% and 47.4% per annum respectively. EPS is expected to grow by 17% per annum. Return on equity is forecast to be -247% in 3 years.
Key information
1.1%
Earnings growth rate
17.0%
EPS growth rate
Biotechs earnings growth | 24.2% |
Revenue growth rate | 47.4% |
Future return on equity | -247.0% |
Analyst coverage | Good |
Last updated | 18 Jun 2024 |
Recent future growth updates
Recent updates
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Apr 09We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Nov 10Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Jun 27Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Mar 13Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Sep 09Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Aug 09We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Jun 09Ovid Therapeutics: Good Entry Point For Investors
Jun 18Ovid Therapeutics appoints Jeff Rona as CFO
Jun 04Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
Apr 16Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Mar 20Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Mar 18We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
Mar 01Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
Jan 25Revisiting Ovid Therapeutics
Jan 14Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?
Dec 21Ovid Therapeutics misses goal in Angelman syndrome treatment
Dec 01Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 7 | -68 | -82 | -38 | 5 |
12/31/2025 | 38 | -48 | -74 | -33 | 8 |
12/31/2024 | 0 | -59 | -80 | -48 | 9 |
3/31/2024 | 0 | -51 | -50 | -50 | N/A |
12/31/2023 | 0 | -52 | -46 | -46 | N/A |
9/30/2023 | 0 | -49 | -43 | -43 | N/A |
6/30/2023 | 0 | -49 | -46 | -46 | N/A |
3/31/2023 | 0 | -51 | -49 | -47 | N/A |
12/31/2022 | 2 | -54 | -57 | -55 | N/A |
9/30/2022 | 1 | -68 | -60 | -58 | N/A |
6/30/2022 | 1 | -66 | -58 | -56 | N/A |
3/31/2022 | 1 | -67 | -63 | -62 | N/A |
12/31/2021 | 208 | 120 | 118 | 119 | N/A |
9/30/2021 | 214 | 123 | 116 | 116 | N/A |
6/30/2021 | 221 | 117 | 125 | 126 | N/A |
3/31/2021 | 221 | 110 | 128 | 128 | N/A |
12/31/2020 | 13 | -81 | -52 | -52 | N/A |
9/30/2020 | 7 | -76 | -54 | -54 | N/A |
6/30/2020 | N/A | -76 | -62 | -62 | N/A |
3/31/2020 | N/A | -67 | -57 | -57 | N/A |
12/31/2019 | N/A | -60 | -51 | -51 | N/A |
9/30/2019 | N/A | -56 | -45 | -45 | N/A |
6/30/2019 | N/A | -53 | -46 | -46 | N/A |
3/31/2019 | N/A | -53 | -46 | -45 | N/A |
12/31/2018 | N/A | -52 | -46 | -46 | N/A |
9/30/2018 | N/A | -50 | -44 | -44 | N/A |
6/30/2018 | N/A | -46 | -43 | -43 | N/A |
3/31/2018 | N/A | -44 | -37 | -37 | N/A |
12/31/2017 | N/A | -65 | N/A | -31 | N/A |
9/30/2017 | N/A | -61 | N/A | -28 | N/A |
6/30/2017 | N/A | -58 | N/A | -23 | N/A |
3/31/2017 | N/A | -53 | N/A | -21 | N/A |
12/31/2016 | N/A | -22 | N/A | -18 | N/A |
9/30/2016 | N/A | -18 | N/A | -14 | N/A |
12/31/2015 | N/A | -13 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OVID is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OVID is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OVID is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OVID's revenue (47.4% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: OVID's revenue (47.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OVID is forecast to be unprofitable in 3 years.